S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Laser breakthrough could send stock soaring 2,467% (Ad)
Federal agency sues Chipotle after a Kansas manager allegedly ripped off an employee's hijab
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
66,000% upside on tiny biotech? (Ad)
Who is Arthur Engoron? Judge weighing future of Donald Trump empire is Ivy League-educated ex-cabbie
Disney, DeSantis legal fights ratchet up as company demands documents from Florida governor
AI Creates New Cancer Drug - In Just 30 Days! (Ad)
Apple says it will fix software problems blamed for making iPhone 15 models too hot to handle
Native Hawaiian neighborhood survived Maui fire. Lahaina locals praise its cultural significance
NASDAQ:NVAX

Novavax (NVAX) Stock Forecast, Price & News

$7.24
+0.08 (+1.12%)
(As of 09/29/2023 ET)
Compare
Today's Range
$7.16
$7.68
50-Day Range
$6.81
$9.74
52-Week Range
$5.61
$25.66
Volume
8.14 million shs
Average Volume
11.29 million shs
Market Capitalization
$683.46 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.00

Novavax MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
383.4% Upside
$35.00 Price Target
Short Interest
Bearish
47.14% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.27
Upright™ Environmental Score
News Sentiment
0.10mentions of Novavax in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.83) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.07 out of 5 stars

Medical Sector

549th out of 972 stocks

Biological Products, Except Diagnostic Industry

79th out of 156 stocks


NVAX stock logo

About Novavax (NASDAQ:NVAX) Stock

Novavax Inc is a biotechnology company that focuses on developing vaccines and biological therapies that combat infectious diseases. The company is headquartered in Gaithersburg, Maryland and has several locations across the United States and Europe. Novavax has a strong track record of developing novel vaccine candidates and has achieved significant milestones in recent years.

In 2020 the company redirected all efforts into finding a vaccine for the COVID-19 pandemic releasing its NVX-CoV2373 vaccine called Nuvaxovid, which has been approved for use in the European Union and Canada. 

Novavax Inc's team is led by CEO John C. Jacobs, who was appointed CEO and board member in Q1 of 2023. Mr. Jacobs has over 25 years of commercial and business operation skills and has demonstrated leadership across multiple therapeutic areas. Mr. Jacobs previously served as CEO and board member at Harmony Biosciences, where he served for five years, leading that company through a successful initial public offering (IPO).

Other notable team members include Dr. Gregory Glenn, the President of Research and Development, with 28 years of vaccine design and regulatory experience. Also noteworthy is Dr. Filip Dubovsky, Novavax Inc's Executive Vice President and Chief Medical Officer, a recognized leader in vaccine development and who joined the company after a 15-year tenure at AstraZeneca, another leading vaccine manufacturer. 

Over the past few years, Novavax has reported steady revenue growth. The company's revenue has increased year over year, reporting net income up each year since 2021. The company's debt levels are high, with total liabilities exceeding total assets for multiple years. Novavax's valuation metrics are in line with industry peers. The company's price-to-earnings ratio and the company's price-to-book ratio are in line with industry peers.

These metrics suggest that the market is valuing Novavax appropriately. Novavax's stock performance has been volatile in recent years. The company's stock price increased significantly in 2020 due to its COVID-19 vaccine development efforts. However, the stock price has since declined, as Novavax has faced delays in obtaining regulatory approvals for its COVID-19 vaccine. Despite these setbacks, the company's long-term prospects remain strong.

The vaccine industry is highly competitive and has significant regulatory and political risks. Novavax faces competition from established pharmaceutical companies, as well as other biotechnology companies that are developing vaccines. However, the company's focus on innovative vaccine candidates, such as its COVID-19 vaccine, gives it a competitive advantage. The vaccine industry is also subject to regulatory risks, as government policy changes can significantly impact the market. Novavax's strong relationships with regulatory agencies give it an advantage in navigating this challenging environment.

Novavax has several growth opportunities in the near term. The company's COVID-19 vaccine has shown promising results in clinical trials and has received regulatory approval in multiple markets. Novavax also has several other vaccine candidates in development, including respiratory syncytial virus (RSV) and influenza vaccines. The company's pipeline of innovative vaccine candidates positions it for long-term growth and success.

Novavax faces several risks and challenges that could impact its long-term success. The company's vaccine candidates are subject to regulatory approval, which can be lengthy and expensive. Novavax also faces significant competition from established pharmaceutical companies and other biotechnology companies. Changes in consumer preferences or shifts in government policies could also impact the market for Novavax's products. 

NVAX Price History

NVAX Stock News Headlines

2 Stocks That Doubled EPS Estimates and Flashing Buy Signals (NVAX)
The second quarter of the 2023 earnings season has drawn to a close. There were many surprises in every sector. However, there were some standout surprises with
Novavax (NASDAQ:NVAX) Trading Up 4.5%
Man Gets Into a Self-Driving Tesla… What Happens Next will Shock Everyone (Video)
“Hi, I’m Teeka Tiwari...I’m about to get in this Tesla and drive up to a facility just a few miles from here to show you what could be the secret behind Elon Musk’s new AI project… What happens next will shock you…”
NVAX, AI, CVNA: The 3 Most Shorted Stocks This Month
Updated COVID boosters to divide America
Europe to decide on Novavax's COVID vaccine in October
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Up 20% in 1 Month, Is This Stock a Buy?
Novavax Stock (NASDAQ:NVAX) Has a Shot at Recovering
Novavax recovers as Pfizer and Moderna lead on Covid booster
US CDC contemplates who should get the new COVID shots
US FDA authorizes updated COVID vaccines
See More Headlines
Receive NVAX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novavax and its competitors with MarketBeat's FREE daily newsletter.

NVAX Company Calendar

Last Earnings
8/08/2023
Today
10/01/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:NVAX
CUSIP
67000210
Employees
1,992
Year Founded
1987

Price Target and Rating

Average Stock Price Forecast
$35.00
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$15.00
Forecasted Upside/Downside
+383.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-657,940,000.00
Pretax Margin
-36.65%

Debt

Sales & Book Value

Annual Sales
$1.98 billion
Book Value
($8.08) per share

Miscellaneous

Free Float
93,554,000
Market Cap
$683.46 million
Optionable
Optionable
Beta
1.69

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Mr. James Patrick Kelly C.F.A. (Age 57)
    Exec. VP, CFO & Treasurer
    Comp: $644.32k
  • Mr. John A. Herrmann IIIMr. John A. Herrmann III (Age 57)
    J.D., Exec. VP & Chief Legal Officer
    Comp: $658.3k
  • Mr. Stanley Charles Erck (Age 75)
    Advisor
    Comp: $1.09M
  • Mr. John Joseph Trizzino B.S. (Age 63)
    M.B.A., Exec. VP, Chief Commercial Officer & Chief Bus. Officer
    Comp: $641.22k
  • Mr. John Charles Jacobs M.B.A. (Age 56)
    Pres, CEO & Director
  • Mr. Richard P. Crowley (Age 66)
    Exec. VP & COO
  • Mr. Troy Morgan Esq. (Age 52)
    J.D., Sr. VP & Chief Compliance Officer
  • Ms. Erika S. Trahan
    Associate Director of Investor & PR
  • Mr. Ian J. Watkins (Age 60)
    Exec. VP & Chief HR Officer
  • Ms. Silvia Taylor M.B.A.
    MBA, Exec. VP and Chief Corp. Affairs & Advocacy Officer













NVAX Stock - Frequently Asked Questions

Should I buy or sell Novavax stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novavax in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" NVAX shares.
View NVAX analyst ratings
or view top-rated stocks.

What is Novavax's stock price forecast for 2023?

4 equities research analysts have issued 1 year target prices for Novavax's stock. Their NVAX share price forecasts range from $15.00 to $55.00. On average, they anticipate the company's share price to reach $35.00 in the next year. This suggests a possible upside of 383.4% from the stock's current price.
View analysts price targets for NVAX
or view top-rated stocks among Wall Street analysts.

How have NVAX shares performed in 2023?

Novavax's stock was trading at $10.28 on January 1st, 2023. Since then, NVAX shares have decreased by 29.6% and is now trading at $7.24.
View the best growth stocks for 2023 here
.

When is Novavax's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our NVAX earnings forecast
.

How were Novavax's earnings last quarter?

Novavax, Inc. (NASDAQ:NVAX) released its quarterly earnings results on Tuesday, August, 8th. The biopharmaceutical company reported $0.58 EPS for the quarter, beating the consensus estimate of ($1.24) by $1.82. The biopharmaceutical company had revenue of $424.40 million for the quarter, compared to analysts' expectations of $264.16 million. The company's revenue was up 128.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($6.53) EPS.

When did Novavax's stock split?

Novavax shares reverse split on the morning of Friday, May 10th 2019. The 1-20 reverse split was announced on Wednesday, May 8th 2019. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 9th 2019. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What guidance has Novavax issued on next quarter's earnings?

Novavax issued an update on its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.50 billion, compared to the consensus revenue estimate of $1.44 billion.

What is Stanley C. Erck's approval rating as Novavax's CEO?

46 employees have rated Novavax Chief Executive Officer Stanley C. Erck on Glassdoor.com. Stanley C. Erck has an approval rating of 71% among the company's employees.

What other stocks do shareholders of Novavax own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novavax investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Egalet (EGLT), Exact Sciences (EXAS) and Pfizer (PFE).

What is Novavax's stock symbol?

Novavax trades on the NASDAQ under the ticker symbol "NVAX."

How do I buy shares of Novavax?

Shares of NVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novavax's stock price today?

One share of NVAX stock can currently be purchased for approximately $7.24.

How much money does Novavax make?

Novavax (NASDAQ:NVAX) has a market capitalization of $683.46 million and generates $1.98 billion in revenue each year. The biopharmaceutical company earns $-657,940,000.00 in net income (profit) each year or ($7.26) on an earnings per share basis.

How many employees does Novavax have?

The company employs 1,992 workers across the globe.

How can I contact Novavax?

Novavax's mailing address is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The official website for the company is www.novavax.com. The biopharmaceutical company can be reached via phone at (240) 268-2000, via email at ir@novavax.com, or via fax at 240-268-2100.

This page (NASDAQ:NVAX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -